# Study Guide: Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer This study guide is based on the ASCO Guideline Update, which provides evidence-based recommendations for using biomarker assays to guide adjuvant treatment decisions for patients with early-stage invasive breast cancer. --- ## Part 1: Key Concepts and Clinical Recommendations ### I. Estrogen Receptor (ER)-Positive, HER2-Negative Breast Cancer This is the primary population for which genomic and protein-based biomarkers are currently validated to guide chemotherapy and endocrine therapy decisions. #### 1. Oncotype DX (21-Gene Recurrence Score) * **Node-Negative Patients:** Clinicians may use the test to guide decisions. If the Recurrence Score (RS) is $\ge$ 26, chemoendocrine therapy should be offered. For patients $\le$ 50 years with an RS of 16–25, chemoendocrine therapy may be offered. * **Node-Positive (1–3 nodes):** * **Postmenopausal:** Use the test to guide decisions; offer chemoendocrine therapy if RS $\ge$ 26. * **Premenopausal:** The test should **not** be offered to guide chemotherapy decisions, as data suggest these patients benefit from chemotherapy regardless of the genomic result. * **$\ge$ 4 Positive Nodes:** Evidence is insufficient to recommend routine use. #### 2. MammaPrint (70-Gene Signature) * **Patients > 50 Years:** May be used in high-clinical-risk patients with 0–3 positive nodes to guide adjuvant decisions. * **Patients $\le$ 50 Years:** Should **not** be used in high-clinical-risk patients with 0–3 positive nodes. * **Low Clinical Risk:** Evidence is insufficient to recommend use regardless of age. #### 3. EndoPredict, Prosigna, and IHC4 * **EndoPredict (12-gene score):** May be used in postmenopausal patients (0–3 positive nodes). It should not be used in premenopausal patients. * **Prosigna (PAM50):** May be used in postmenopausal patients with node-negative disease. Evidence is inconclusive for those with 1–3 positive nodes. * **IHC4:** May be used in node-negative or 1–3 node-positive cases only if multigene assays are unavailable and the laboratory has validated the score. #### 4. Ki67 * **Prognostic Use:** Most informative at the extremes: $< 5\%$ (low proliferation) or $> 30\%$ (high proliferation). * **Treatment Selection:** A Ki67 score of $\ge 20\%$ (via FDA-approved test) may be used to offer two years of abemaciclib plus endocrine therapy in node-positive patients with a high risk of recurrence. --- ### II. Extended Endocrine Therapy (Years 5–10) Guidance for patients who have completed 5 years of primary endocrine therapy without recurrence: | Biomarker | Recommendation | | :--- | :--- | | **Breast Cancer Index (BCI)** | May be offered to patients with 0–3 positive nodes to guide decisions on extended therapy (tamoxifen or AIs). | | **CTS5 Web Tool** | May be used in postmenopausal patients to estimate the risk of late recurrence (years 5–10). | | **Oncotype DX / EndoPredict / Prosigna** | Insufficient evidence to guide extended endocrine therapy decisions. | --- ### III. HER2-Positive and Triple-Negative Breast Cancer (TNBC) * **General Rule:** Multiparameter gene expression or protein assays (Oncotype DX, MammaPrint, etc.) should **not** be used to guide adjuvant treatment for HER2-positive or TNBC patients. --- ### IV. Emerging Biomarkers Currently, the following biomarkers are **not recommended** for routine clinical use in early-stage breast cancer to guide (neo)adjuvant decisions: * **Tumor-Infiltrating Lymphocytes (TILs):** Though prognostic in TNBC and HER2-positive disease, they do not yet support treatment changes outside of research. * **PD-L1 Testing:** Utility is clear in metastatic TNBC but not yet established in the early-stage setting. * **Circulating Tumor Cells (CTC) and ctDNA:** While these show promise for detecting molecular relapse or predicting recurrence, evidence for clinical utility in guiding treatment is currently lacking. --- ## Part 2: Short-Answer Practice Questions 1. **What is the specific Oncotype DX Recurrence Score (RS) threshold at which chemoendocrine therapy is strongly recommended for postmenopausal node-negative patients?** * *Answer:* A score of $\ge$ 26. 2. **Why is MammaPrint not recommended for high-clinical-risk patients aged 50 or younger?** * *Answer:* Updated MINDACT trial results showed that adjuvant chemotherapy was associated with a benefit in women $\le$ 50 years even if they had a low genomic risk. 3. **Which biomarker can be used to determine if a node-positive patient should be offered two years of abemaciclib?** * *Answer:* Ki67 (specifically a score of $\ge 20\%$). 4. **In which scenario is the Breast Cancer Index (BCI) specifically recommended?** * *Answer:* To guide decisions about extended endocrine therapy (beyond the initial 5 years) in patients with 0–3 positive nodes. 5. **For patients with $\ge$ 4 positive nodes, what is the ASCO recommendation regarding the use of genomic assays like Oncotype DX or MammaPrint?** * *Answer:* Evidence is insufficient for routine use, though they are prognostic and may be used for shared physician-patient decision-making. 6. **Can EndoPredict be performed in local laboratories?** * *Answer:* Yes, unlike some other tests, it can be performed reliably in local laboratories. 7. **What does the CTS5 web tool calculate?** * *Answer:* It estimates the risk of late recurrence (between years 5 and 10) in postmenopausal patients. 8. **Is PD-L1 testing recommended for early-stage TNBC to guide chemotherapy decisions?** * *Answer:* No, the evidence is currently insufficient to recommend its use in the early setting. --- ## Part 3: Essay Questions for Deeper Exploration 1. **Analyze the role of menopausal status and age in the application of genomic biomarkers.** * *Focus:* Discuss how Recommendations 1.6 and 1.9 highlight the differences in chemotherapy benefit for premenopausal vs. postmenopausal women, specifically addressing why tests like Oncotype DX and MammaPrint have restricted utility in younger women with node-positive or high-clinical-risk disease. 2. **Evaluate the clinical utility vs. the clinical validity of ctDNA and CTCs in early-stage breast cancer.** * *Focus:* Define the difference between a biomarker being "prognostic" (validity) and "guiding treatment" (utility). Use the source context to explain why these markers are not yet recommended despite their ability to predict recurrence. 3. **Compare and contrast the biomarkers used for extended endocrine therapy (BCI vs. CTS5).** * *Focus:* Explain that BCI provides a predictive benefit for the treatment itself, whereas CTS5 is a multivariate predictor using clinical variables (size, nodes, grade, age) to estimate the risk of late recurrence. Discuss the complications of using both (potential for discordant results). --- ## Part 4: Glossary of Important Terms * **Adjuvant Therapy:** Treatment given after the primary treatment (surgery) to increase the chances of a cure. * **BCI (Breast Cancer Index):** A genomic test used primarily to predict the benefit of extending endocrine therapy beyond five years. * **Chemoendocrine Therapy:** A treatment regimen that combines chemotherapy with hormone (endocrine) therapy. * **ctDNA (Circulating Tumor DNA):** DNA released by tumor cells into the blood; used as an emerging marker for molecular residual disease. * **CTS5 (Clinical Treatment Score post-5 years):** A web-based tool that uses clinical and histological variables to estimate late recurrence risk in postmenopausal women. * **EndoPredict:** A 12-gene risk score that integrates genomic and anatomic factors (tumor size and nodal status). * **HER2 (Human Epidermal Growth Factor Receptor 2):** A protein that can promote the growth of cancer cells; its status determines if a cancer is HER2-positive or negative. * **IHC4:** A score combining four immunohistochemical markers: ER, PR, HER2, and Ki67. * **Ki67:** A protein that serves as a cellular marker for proliferation (how fast cells are dividing). * **MammaPrint:** A 70-gene signature test used to assess the risk of recurrence and potential chemotherapy benefit. * **Node-Negative:** Cancer that has not spread to the lymph nodes. * **Oncotype DX:** A 21-gene recurrence score (RS) assay used to predict chemotherapy benefit in ER-positive breast cancer. * **Prosigna (PAM50):** A genomic test that identifies molecular subtypes and generates a risk-of-recurrence (ROR) score. * **TILs (Tumor-Infiltrating Lymphocytes):** White blood cells that have moved from the blood into a tumor; an emerging prognostic marker in TNBC and HER2-positive cancer. * **TNBC (Triple-Negative Breast Cancer):** A type of breast cancer that tests negative for estrogen receptors, progesterone receptors, and HER2 protein.